Journal Home
Search for

Volume 122, Issue 1, Pages 36-41 (July 2008)


View previous. 20 of 58 View next.

Advances in basic and clinical immunology in 2007

Javier Chinen, MD, PhDCorresponding Author Informationemail address, William T. Shearer, MD, PhD

Received 23 April 2008; accepted 25 April 2008. published online 03 June 2008.

In 2007, there was significant progress in the area of basic immunology, including investigations that led to a better understanding of the function of antigen-presenting cells, such as the secretion of cytokines that inhibit or induce allergic inflammation on antigen stimulation. Mechanisms of IgE function were better characterized, and the clonality of IgE-producing B cells in allergic responses of monosensitized patients was demonstrated. The hygiene hypothesis was re-examined, with most of the evidence suggesting that the increase of atopy prevalence is best explained by the absence of TH1 responses rather than the absence of regulatory T cells. The effects of the environment in the allergic inflammation of the lung received new emphasis. Similar progress took place in the area of clinical immunology. Immune adverse reactions to drugs, such as the toxicity of carbamazepine-specific T cells and the safety and efficacy of drugs for the treatment of hereditary angioedema, were better characterized. There were advances in the molecular characterization of primary immunodeficiencies and their management, remarkably the discovery of signal transducer and activator of transcription 3 gene mutations as the cause of hyper-IgE syndrome. Long-term outcomes of bone marrow transplantation for severe combined immunodeficiencies confirmed the efficacy of this therapy.

Department of Pediatrics, Allergy and Immunology Section, Baylor College of Medicine, Houston, Tex

Corresponding Author InformationReprint requests: Javier Chinen, MD, PhD, Department of Pediatrics, Allergy and Immunology Section, Baylor College of Medicine, 6621 Fannin St FC 330.01, Houston, TX 77030.

 Supported by National Institutes of Health Grants AI27551, AI069441, HD41983, HD052102, RR0188, HL079533, HL72705, HL78522, and RAT003084A and contract AI41089; the Pediatric Research and Education Fund, Baylor College of Medicine; and the David Fund, the Pediatrics AIDS Fund, and the Immunology Research Fund, Texas Children's Hospital.

 Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(08)00779-3

doi:10.1016/j.jaci.2008.04.035


View previous. 20 of 58 View next.